Skip to main content

Table 4 Drug-Related Adverse Events Reported by ≥ 15% of Patients Who Received Vorinostat Combination Therapy in the Vorinostat Clinical Trial Program (Data Cut-Off April 2008)

From: Vorinostat in solid and hematologic malignancies

Adverse Event No. (%) of Patients (N= 157)
  All Grades Grade 3 or 4
Nausea 76 (48.4) 8 (5.1)
Diarrhea 64 (40.8) 9 (5.7)
Fatigue 54 (34.4) 21 (13.4)
Vomiting 49 (31.2) 6 (3.8)
Anorexia 32 (20.4) 4 (2.5)
Dehydration 28 (17.8) 6 (3.8)
Thrombocytopenia 25 (15.9) 15 (9.6)
Anemia 25 (15.9) 4 (2.5)